Shift work disrupts the internal clock, and the search for agents that can accelerate circadian resynchronization has drawn attention to neuropeptides. Among them, Selank (a synthetic heptapeptide analogue of tuftsin) and DSIP (delta sleep-inducing peptide) have been studied in Russian laboratories for their effects on sleep architecture and stress adaptation. Co-administration of these two compounds is not yet a standard protocol, but preclinical work suggests a complementary mechanism that may be relevant for workers rotating through night schedules.
The rationale emerges from separate lines of investigation. DSIP was first isolated from rabbit cerebral venous blood during electrically induced sleep and later shown to promote spindle-rich sleep in animal models (Khavinson 2014). Selank, developed at the Institute of Molecular Genetics, exerts anxiolytic effects without sedation and appears to modulate the expression of circadian clock genes (Anisimov 2016). When shift work forces a misalignment between the suprachiasmatic nucleus and peripheral oscillators, the combination might address both the sleep-onset difficulty and the neuroendocrine stress that accompanies phase shifting.
Except , and this matters , the evidence is almost entirely from rodent models and small human observational studies. The translational gap is wide, and the mechanisms are inferred rather than directly demonstrated in shift workers. Still, the body of work from the St. Petersburg school of gerontology and bioregulation provides a coherent framework for thinking about peptide-mediated circadian support.
The Research School Behind the Hypothesis
Much of the relevant literature originates from the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson and his colleagues have spent decades cataloguing the effects of short peptides on physiological rhythms. Their work on Epitalon (a tetrapeptide Ala-Glu-Asp-Gly) established that certain peptides can influence pineal melatonin secretion and clock gene expression in aging animals (Khavinson 2012). This line of inquiry naturally extended to DSIP and, later, to Selank.
Khavinson's group published a series of experiments in which DSIP was administered to rats subjected to experimental jet lag. The peptide shortened the time required for locomotor activity rhythms to re-entrain to a new light-dark cycle, an effect that correlated with accelerated shifts in the expression of Per1 and Cry1 in the suprachiasmatic nucleus (Khavinson 2014). Separately, Anisimov and colleagues showed that Selank, while primarily studied as an anxiolytic, upregulated Bmal1 in the hippocampus of rats exposed to chronic mild stress (Anisimov 2016). The convergence of these findings on core clock components makes the co-administration hypothesis plausible.
DSIP and Sleep Architecture Under Phase Shift
DSIP (delta sleep-inducing peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its name reflects the original observation that intraventricular infusion increased delta-wave activity in the EEG of recipient rabbits. Later work demonstrated that systemic administration also influences sleep, though the effects are dependent on the baseline state of the organism. In stressed animals, DSIP promotes slow-wave sleep. In rested animals, the effect is less pronounced.
For the shift worker, the relevant property is DSIP's apparent ability to facilitate sleep onset during the circadian low point of alertness. A study by Sudakov (2010) monitored sleep latency in human volunteers subjected to a 6-hour phase advance. Those who received DSIP before the shifted bedtime fell asleep faster than placebo controls, and their sleep efficiency during the first half of the night was higher. The mechanism is not fully understood, but DSIP interacts with the GABAergic system and may reduce the hyperarousal that often prevents daytime sleep after a night shift.
Or maybe not. Some Western researchers have failed to replicate the sleep-promoting effects of DSIP in healthy volunteers, raising questions about whether the peptide's action is state-dependent. The Russian literature emphasizes that DSIP works best when the organism is under homeostatic pressure to sleep, a condition that certainly applies after a night of work.
Selank and Stress-Adaptation During Circadian Misalignment
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin. Its development at the Institute of Molecular Genetics was driven by the search for an anxiolytic that would not cause sedation or cognitive impairment. Preclinical and clinical studies confirmed that Selank reduces anxiety and improves cognitive performance under stress, effects that are linked to modulation of the expression of brain-derived neurotrophic factor and changes in monoamine turnover (Seredenin 2013).
What makes Selank interesting for circadian resynchronization is its influence on the hypothalamic-pituitary-adrenal axis. Shift work is a chronic stressor that elevates cortisol and disrupts the normal diurnal rhythm of glucocorticoid secretion. Selank appears to normalize cortisol rhythms in animal models of chronic stress, an effect that may be mediated through its action on the expression of Clock and Bmal1 in the adrenal glands (Anisimov 2016). If the adrenal clock can be reset more quickly, the misalignment between the central pacemaker and peripheral tissues might be reduced.
Another property of Selank is its ability to enhance the expression of interleukin-6 in certain contexts, a cytokine that has a complex relationship with sleep regulation. Some evidence suggests that IL-6 can promote slow-wave sleep when administered centrally, though peripheral elevations are associated with insomnia. The net effect of Selank on sleep is therefore difficult to predict and likely depends on the timing of administration.
Co-Administration: Complementary or Redundant?
The case for co-administration rests on the idea that DSIP and Selank act on different nodes of the circadian system. DSIP primarily facilitates sleep onset and slow-wave sleep generation, which is critical for the restorative function of sleep and for the consolidation of the new circadian phase. Selank, by contrast, addresses the stress response and may accelerate the molecular resetting of peripheral clocks. In theory, the combination could produce a faster and more complete resynchronization than either peptide alone.
There is, however, no published study that directly tests this combination in shift workers. The closest precedent is a small experiment by Khavinson's group in which rats were subjected to a 12-hour phase shift and treated with DSIP, Selank, or both. The combination group showed the fastest re-entrainment of body temperature rhythms and the lowest corticosterone levels during the transition period (Khavinson 2015, unpublished conference abstract). These data are suggestive but far from definitive.
One concern is that DSIP and Selank might interact pharmacodynamically in ways that are not beneficial. Both peptides have been reported to influence GABAergic transmission, and excessive GABAergic tone could lead to daytime drowsiness or cognitive slowing. The timing of administration would need to be carefully considered: DSIP before the sleep period, Selank perhaps upon waking to support alertness and stress resilience. This staggered approach has not been systematically studied.
How It Relates to Western Literature
Western chronobiology has largely focused on melatonin and light therapy for circadian resynchronization, with more recent interest in orexin antagonists and melatonin receptor agonists. Peptides like DSIP and Selank have received little attention outside of Russia, partly because of limited English-language publications and partly because of skepticism about the robustness of the early findings. A comparison of Tesamorelin and DSIP for GH-mediated slow-wave sleep enhancement highlights the challenges of translating peptide sleep research across different regulatory and scientific cultures.
Nevertheless, the concept of using multiple peptides to target different aspects of circadian disruption is consistent with emerging Western research on combination chronotherapeutics. The recognition that peripheral clocks in the liver, muscle, and adipose tissue can be manipulated independently of the central clock has opened the door to multi-target strategies. Selank's effects on adrenal clock genes and DSIP's effects on sleep architecture could, in principle, be complementary components of such a strategy.
Open Questions and Future Directions
The most pressing question is whether the rodent findings will translate to human shift workers. The circadian systems of nocturnal rodents and diurnal humans differ in important ways, and the stressors of shift work are more complex than a simple phase shift in the laboratory. Field studies that monitor sleep, performance, and hormonal rhythms in actual shift workers treated with DSIP and Selank would be needed to assess efficacy.
Another open question concerns the optimal timing and dosage. The half-lives of these peptides in humans are not well characterized, and the relationship between plasma concentration and central effect is unclear. If Selank's anxiolytic effect outlasts its clock-resetting effect, for example, the timing of doses might need to be adjusted to avoid carryover into the sleep period.
Finally, the safety of chronic co-administration has not been established. DSIP has been administered to humans in short-term studies without serious adverse effects, and Selank has a favorable safety profile in clinical trials for anxiety disorders. But the combination has not been tested for longer than a few weeks in any published study. The potential for tolerance, rebound insomnia, or endocrine disruption with prolonged use is unknown.
Long-term safety data for many peptides discussed here is limited. Risk profiles should be interpreted accordingly.